G W Botteron1, J M Smith. 1. Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Abstract
INTRODUCTION: Adenosine is an antiarrhythmic agent widely used for the diagnosis and treatment of supraventricular tachyarrhythmias. Bolus administration of adenosine has been associated with transient atrial fibrillation, but the underlying mechanisms have not yet been delineated, due in part to the technical limitations resulting from adenosine's short half-life. In this study, the rapid, repetitive activation of atrial tissue during atrial fibrillation was exploited to yield a nearly continuous estimate of atrial refractoriness, enabling a description of adenosine's action on atrial refractoriness in humans. METHODS AND RESULTS: Simultaneous right and left atrial, narrow-spaced, bipolar electrograms were recorded in 15 patients before, during, and after bolus administration of 12 mg of adenosine during atrial fibrillation. By estimating the local cycle length of excitation from the atrial activation frequency, a refractory period index (RPI) of local tissue was obtained. Adenosine dramatically increased the activation frequency from 6.4 +/- 0.7 to 12.2 +/- 12.2 Hz in the right atrium and from 6.1 +/- 0.6 to 8.7 +/- 1.2 Hz in the left atrium, corresponding to a decrease in the RPI from 156 to 82 msec (P < 0.0001) and from 163 to 116 msec (P < 0.0001), respectively. The magnitude of adenosine's effect was greater (47% vs 29% shortening) (P < 0.001) and the duration of adenosine's effect longer (28 vs 19 sec) (P < 0.05) in the right compared to the left atrium. CONCLUSION: Adenosine, at doses routinely used clinically, produces a transient, but spatially and temporally inhomogeneous, shortening of atrial refractoriness, which may explain the increased propensity toward atrial fibrillation associated with its use.
INTRODUCTION:Adenosine is an antiarrhythmic agent widely used for the diagnosis and treatment of supraventricular tachyarrhythmias. Bolus administration of adenosine has been associated with transient atrial fibrillation, but the underlying mechanisms have not yet been delineated, due in part to the technical limitations resulting from adenosine's short half-life. In this study, the rapid, repetitive activation of atrial tissue during atrial fibrillation was exploited to yield a nearly continuous estimate of atrial refractoriness, enabling a description of adenosine's action on atrial refractoriness in humans. METHODS AND RESULTS: Simultaneous right and left atrial, narrow-spaced, bipolar electrograms were recorded in 15 patients before, during, and after bolus administration of 12 mg of adenosine during atrial fibrillation. By estimating the local cycle length of excitation from the atrial activation frequency, a refractory period index (RPI) of local tissue was obtained. Adenosine dramatically increased the activation frequency from 6.4 +/- 0.7 to 12.2 +/- 12.2 Hz in the right atrium and from 6.1 +/- 0.6 to 8.7 +/- 1.2 Hz in the left atrium, corresponding to a decrease in the RPI from 156 to 82 msec (P < 0.0001) and from 163 to 116 msec (P < 0.0001), respectively. The magnitude of adenosine's effect was greater (47% vs 29% shortening) (P < 0.001) and the duration of adenosine's effect longer (28 vs 19 sec) (P < 0.05) in the right compared to the left atrium. CONCLUSION:Adenosine, at doses routinely used clinically, produces a transient, but spatially and temporally inhomogeneous, shortening of atrial refractoriness, which may explain the increased propensity toward atrial fibrillation associated with its use.
Authors: Ning Li; Thomas A Csepe; Brian J Hansen; Lidiya V Sul; Anuradha Kalyanasundaram; Stanislav O Zakharkin; Jichao Zhao; Avirup Guha; David R Van Wagoner; Ahmet Kilic; Peter J Mohler; Paul M L Janssen; Brandon J Biesiadecki; John D Hummel; Raul Weiss; Vadim V Fedorov Journal: Circulation Date: 2016-07-26 Impact factor: 29.690
Authors: Turhan Yavuz; Barry Bertolet; Yavuz Bebooul; Bulent Tunerir; Recep Aslan; Ahmet Ocal; Erdooan Ybribim; Ali Kutsal Journal: Clin Cardiol Date: 2004-06 Impact factor: 2.882
Authors: Aleksei V Mikhailov; Anuradha Kalyanasundaram; Ning Li; Shane S Scott; Esthela J Artiga; Megan M Subr; Jichao Zhao; Brian J Hansen; John D Hummel; Vadim V Fedorov Journal: J Mol Cell Cardiol Date: 2020-10-29 Impact factor: 5.000
Authors: Gurpreet Singh Dhillon; Nikhil Ahluwalia; Shohreh Honarbakhsh; Adam Graham; Antonio Creta; Hakam Abbass; Anthony Chow; Mark J Earley; Pier D Lambiase; Richard J Schilling; Ross J Hunter Journal: PLoS One Date: 2021-03-25 Impact factor: 3.240
Authors: Brian J Hansen; Jichao Zhao; Katelynn M Helfrich; Ning Li; Alexander Iancau; Alexander M Zolotarev; Stanislav O Zakharkin; Anuradha Kalyanasundaram; Megan Subr; Nawshin Dastagir; Roshan Sharma; Esthela J Artiga; Nicholas Salgia; Mustafa M Houmsse; Omar Kahaly; Paul M L Janssen; Peter J Mohler; Nahush A Mokadam; Bryan A Whitson; Muhammad R Afzal; Orlando P Simonetti; John D Hummel; Vadim V Fedorov Journal: J Am Heart Assoc Date: 2020-10-02 Impact factor: 5.501